$VKTX (-0,59 %)

- R&D expenses: $31.0M, +51% YoY

- Net loss: $35.4M vs $24.6M YoY

- Strong cash position: $903M vs $362M YoY

CEO Brian Lian: "2024 was an exciting and extremely productive year for Viking. During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD."

🌱Revenue & Growth

- No revenue reported in Q4 2024 and Q4 2023

- R&D expenses: $31.0M vs $20.5M in Q4 2023

- G&A expenses: $15.3M vs $8.8M in Q4 2023

💰Profits & Financials

- Q4 Net loss: $35.4M ($0.32/share) vs $24.6M ($0.25/share) YoY

- FY2024 Net loss: $110.0M ($1.01/share) vs $85.9M ($0.91/share) YoY

- Cash and investments: $903M as of Dec 31, 2024

- Interest income: $10.8M vs $4.7M in Q4 2023

📌Business Highlights

- Completed Phase 2 VENTURE study of VK2735 for obesity with up to 14.7% weight loss

- Initiated Phase 2a VENTURE-Oral Dosing trial for oral VK2735

- Reported positive Phase 1b results for VK0214 in X-ALD treatment

🔮Future Outlook

- Phase 3 studies for subcutaneous VK2735 planned for Q2 2025

- Phase 2 VENTURE-Oral data expected in 2H 2025

- Plans to file IND for DACRA program in 2025

- Upcoming investor conferences in February-April 2025

TTWROR: 60.5%

$HIMS (-0,93 %)

$SOFI (-1,11 %)

$RKLB (-1,23 %)

$BTC (+0,45 %)

$SOL (-0,84 %)

$AMZN (-0,95 %)

$BABA (-1,79 %)

$ASML (+1,5 %)

$NU (-1,85 %)

$UBER (-0,6 %)

$AMD (-0,28 %)

$HITI (-0,24 %)

$REAX (+0 %)

$1211 (-0,37 %)

$9866 (-1,25 %)

$TMDX (-0,9 %)

$VKTX (-0,59 %)

$BATS (-1,11 %)

$ISP (-1,15 %)

$PYPL (-0,57 %)

$AMGN (-1 %) MariTide demonstrated up to ~20% average weight loss at 52 weeks without a weight loss plateau in people living with obesity or overweight (Amgen Inc)

- Positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. The study also showed people living with obesity or overweight and Type 2 diabetes, who typically lose less weight on GLP-1 therapies, achieved up to ~17% average weight loss, also without a weight loss plateau, and lowered their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52. In summary, in both study populations, a weight loss plateau was not observed, again indicating the potential for further weight loss beyond 52 weeks.

- MariTide also demonstrated robust and clinically meaningful improvements in cardiometabolic parameters, including blood pressure, triglycerides and high-sensitivity C-reactive protein (hs-CRP) across doses. There were no significant increases in free fatty acids.

Wall Street was expecting a 25% weight loss result.

$NVO (-0,49 %)
$LLY (-0,42 %) and possibly $VKTX (-0,59 %) dodged another bullet with $AMGN obesity results disappointing